22 November 2011 / Sukaina Virji
Novartis will target filings in the Middle East next as part of its licence agreement with GW Pharmaceuticals for the cannabis-based multiple sclerosis-related spasticity treatment Sativex. These are slated for the first half of 2012, GW's managing director Justin Gover told Scrip.
Más
Ver también:
No hay comentarios:
Publicar un comentario